教員氏名徳田裕（とくだゆたか）取得学位医学博士現在の身分（役職名）教授専門分野乳腺内分泌外科学現在の研究課題所属学会日本外科学会，日本乳癌学会，日本癌学会，日本癌治療学会，日本臨床腫瘍学会，日本臨床外科学会，日本造血細胞移植学会 American Society of Clinical Oncology, American Association for Cancer Research 教員紹介領域（医学部組織）外科学系乳腺・内分泌外科学専門分野キーワード乳腺内分泌研究内容近年，日本人の死亡原因の第１位は，悪性新生物となり，乳癌の罹患率は年々増加している．現在では，女性の悪性新生物の第１位を占め，今後もさらに増加することが予想されている．したがって，乳癌に対するさらなる診断技術の向上と治療法の開発が期待されている．そこで，当研究室では，最近，１．診断技術の向上を目的に，（１）Ki-67 index の臨床的意義の確立．２．治療成績の向上を目的に，（１） HER2 陽性乳癌における新規 anthracycline と trastuzumab 併用の有用性の検討，（２）apoptosis 誘導 HER2 ペプチドによるワクチン療法の開発，などの研究をすすめている．その他にも新しい薬剤の治験ならびに多施設共同研究による臨床研究をおこなっている主要論文： 1. Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T,Oshitanai R, Morioka T, Tuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y.Prognostic Significance of the Ki67 Scoring Categories in Breast Cancer Subgroups. Clin Breast Cancer. 2013 Dec 30. 2. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013 Dec;10(12):711-9. 3. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. 2013 Feb 13. 4. Inaji H, Iwata H, Nakayama T, Yamamoto N, Sato Y, Tokuda Y, Aogi K, Saji S, Watanabe K, Saito T, Yoshida M, Sato N, Saeki T, Takatsuka Y, Kuranami M, Yamashita H, Kikuchi A, Tabei T, Ikeda T, Noguchi S. Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Cancer Sci. 2012 Sep;103(9):1708-13. 5. Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, Mori K, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci. 2012 Aug;103(8):1508-12. 6. 6. Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer. 2014 Jan;21(1):20-7. 7. Tamaki Y, Sato N, Homma K, Takabatake D, Nishimura R, Tsujimoto M, Yoshidome K, Tsuda H, Kinoshita T, Kato H, Taniyama K, Kamio T, Nakamura S, Akiyama F, Noguchi S; Japanese One-Step Nucleic Acid Amplification Study Group. Routine clinical use of the one-step nucleic acid amplification assay for detection of sentinel lymph node metastases in breast cancer patients: results of a multicenter study in Japan. Cancer. 2012 Jul 15;118(14):3477-83. 8. Nakamura S, Ando M, Masuda N, Aogi K, Ino H, Iwata H, Tokuda Y, Yamamoto N, Kasai H, Takeuchi M, Tsuda H, Akiyama F, Kurosumi M, Fujiwara Y. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. Clin Breast Cancer. 2012 Feb;12(1):49-56. 9. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer. 2012 Apr 15;118(8):2039-47. 10. Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004-2009. Breast Cancer. 2012 Jan;19(1):1-3.. 11. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012 Feb 20;30(6):593-9. 12. Niikura N, Kimura M, Iwamoto T, Hayashi N, Shintoku J, Saito Y, Suzuki Y, Tokuda Y. Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. Breast Cancer. 2013 Jan;20(1):67-74. 13. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20;29(24):3214-23. Copyright (C) 2014 東海大学大学院医学研究科. All Rights Reserved.